- Home
- TRU vs DGX Comparison
TRU vs DGX Comparison
Compare TRU & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRU
- DGX
- Stock Information
- Founded
- TRU 1968
- DGX 1967
- Country
- TRU United States
- DGX United States
- Employees
- TRU N/A
- DGX N/A
- Industry
- TRU Finance: Consumer Services
- DGX Medical Specialities
- Sector
- TRU Finance
- DGX Health Care
- Exchange
- TRU Nasdaq
- DGX Nasdaq
- Market Cap
- TRU 18.0B
- DGX 19.2B
- IPO Year
- TRU 2015
- DGX 1996
- Fundamental
- Price
- TRU $82.94
- DGX $169.16
- Analyst Decision
- TRU Buy
- DGX Buy
- Analyst Count
- TRU 12
- DGX 13
- Target Price
- TRU $116.55
- DGX $178.38
- AVG Volume (30 Days)
- TRU 2.0M
- DGX 1.1M
- Earning Date
- TRU 04-24-2025
- DGX 04-22-2025
- Dividend Yield
- TRU 0.55%
- DGX 1.89%
- EPS Growth
- TRU N/A
- DGX 2.67
- EPS
- TRU 1.45
- DGX 7.69
- Revenue
- TRU $4,183,800,000.00
- DGX $9,872,000,000.00
- Revenue This Year
- TRU $6.15
- DGX $10.28
- Revenue Next Year
- TRU $10.74
- DGX $3.91
- P/E Ratio
- TRU $57.35
- DGX $22.01
- Revenue Growth
- TRU 9.20
- DGX 6.70
- 52 Week Low
- TRU $66.07
- DGX $125.42
- 52 Week High
- TRU $113.17
- DGX $178.87
- Technical
- Relative Strength Index (RSI)
- TRU 40.72
- DGX 51.72
- Support Level
- TRU $82.77
- DGX $165.10
- Resistance Level
- TRU $88.81
- DGX $168.14
- Average True Range (ATR)
- TRU 2.71
- DGX 3.24
- MACD
- TRU 0.20
- DGX -0.52
- Stochastic Oscillator
- TRU 35.15
- DGX 51.85
About TRU TransUnion
TransUnion is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries, and about a quarter of its revenue comes from international markets.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.